MLN4924 therapy as a novel approach in cancer treatment modalities. (3rd March 2016)

• Record Type: Journal Article
• Authors: Oladghaffari, Maryam; Islamian, Jalil Pirayesh; Baradaran, Behzad; Monfared, Ali Shabestani
• Is Part Of: Journal of chemotherapy. Volume 28:Number 2(2016:Apr.)
• Page Start: 74
• Page End: 82
• Publication Date: 2016-03-03
• Subjects: Apoptosis -- Cancer treatment -- MLN4924 -- NEDD8 activating enzyme -- Ubiquitin-proteasome system (UPS) -- UPS inhibitors (UPSI); Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; 615.58
• DOI: 10.1179/1973947815Y.0000000066
• Languages: English
• ISSNs: 1120-009X

Abstract

Abstract : MLN4924 is an investigational and a newly discovered small molecule that is a potent and selective inhibitor of the NEDD8 (Neural precursor cell-Expressed Developmentally down-regulated 8) Activating Enzyme (NAE), a pivotal regulator of the Cullin Ring Ligases E3 (CRL), which has been implicated recently in DNA damage. MLN4924 effectively inhibits tumour cell growth by inducing all three common types of death, namely apoptosis, autophagy and senescence and it was also reported that the formation of capillary vessels was significantly suppressed by MLN4924.In this review, we are going to highlight the molecular mechanism of MLN4924 in cancer therapy and its pros and cons in cancer therapy.